乳腺癌超大分割联合同步推量:早期不良反应分析
研究前瞻性分析了西班牙16个放射肿瘤中心2020年4月至12月收治的242例保乳术后乳腺癌患者,接受超大分割联合瘤床同步推量29 Gy方案,中位年龄61岁,中位随访6个月。结果显示该方案临床可行、安全,未出现过多早期不良反应,但原文指出需进一步分析晚期毒性。
要点
- 242例保乳术后乳腺癌患者接受超大分割联合同步推量29 Gy,中位年龄61岁。
- 6个月时97%患者红斑为G0,3%为G1,0%为G2;水肿G1为11.4%,G2为2.5%。
- 计划靶区乳腺体积和推量体积对不良反应无统计学显著影响。
核心结论
- 对早期乳腺癌患者行超大分割联合瘤床同步推量29 Gy在临床上可行、安全,未出现过多早期不良反应。
- 原文指出需要进一步分析晚期毒性。
研究设计与样本
- 前瞻性登记并分析病例系列,来自西班牙16个放射肿瘤中心。
- 2020年4月至12月共242例乳腺癌患者接受辅助放疗,中位年龄61岁(四分位距53-70)。
- 全部患者接受保乳手术,27.7%接受化疗,85.1%接受内分泌治疗。
- 60.7%患者接受29 Gy同步推量,39.3%无推量指征;5.4%患者接受瘤床同步推量及区域淋巴结照射。
主要发现
- 66.1%患者接受容积旋转调强放疗,30.6%接受调强放疗,0.4%(1例)接受三维技术,2.9%(7例)接受调强放疗-三维联合技术,16.9%使用深吸气屏气。
- 治疗结束时红斑G0为56.1%、G1为43.1%、G2为0.8%;水肿G1为14.6%、G2不足1%。
- 6个月后红斑G0为97%、G1为3%、G2为0%;水肿G1为11.4%、G2为2.5%。
- 计划靶区乳腺体积和计划靶区推量体积对不良反应无统计学显著影响。
关键数值与推荐
- 瘤床同步推量剂量为29 Gy。
- 原文未报告不良反应分级的判定标准。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需要进一步分析晚期毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The FAST-Forward study paved the way for ultrahypofractionation (UHF) in breast cancer. We prospectively registered and analyzed our case series receiving UHF + simultaneous integrated boost (SIB) to further reduce the treatment to a total of 5 days. The study aimed to present the 6-month early side effects results of the first patients treated with this scheme in 16 radiation oncology centers in Spain. METHODS AND MATERIALS: A total of 242 breast cancer patients received adjuvant radiation therapy between April and December 2020. The median age was 61 years (interquartile range, 53-70). All patients underwent breast-conserving surgery. Chemotherapy (QT) was administered to 27.7%, and endocrine therapy to 85.1%. A SIB of 29 Gy was applied to 60.7% of the patients, while 39.3% did not have a boost indication. Breast radiation therapy (RT) with SIB to the tumor bed and regional node irradiation was done in 5.4 % of patients. RESULTS: Most patients were treated with Volumetric modulated arc therapy (66.1%) and intensity modulated RT (30.6%). One patient received treatment by 3-dimensional techniques (0.4%) and 7 patients (2.9%) a combined intensity modulated RT-3-dimensional technique. Deep inspiration breath-hold was used in 16.9% of cases. At the end of treatment, erythema grade (G) 0 was presented in 56.1%, G1 in 43.1%, and G2 in 0.8%. G1 edema was observed in 14.6% and less than 1% had G2. After 6 months, 97% had G0 erythema, 3% G1, and 0% G2, while G1 edema was observed in 11.4% and G2 in 2.5%. No statistically significant impact on side effects was found for planning target volume breast and planning target volume boost volumes. CONCLUSIONS: UHF with SIB of 29 Gy to the tumor bed in patients with early-stage breast cancer is clinically feasible, safe, and free of an excess of early side effects. Further analysis of late toxicity is needed.
引用
- Dzhugashvili M, Serradilla A, Fernández-Ibiza J, et al. Ultrahypofractionation and Simultaneous Integrated Boost in Breast Cancer: Early Side Effects Analysis. Int J Radiat Oncol Biol Phys. 2025. PMID: 40072398. doi:10.1016/j.ijrobp.2025.02.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。